Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Using the DNA Integrity Number (DIN) to analyze DNA quality in specimens collected from liquid-based cytology after fine needle aspiration of breast tumors and lesions.
Hoshino A, Oana Y, Ohi Y, Maeda Y, Omori M, Takada Y, Ikeda T, Sotome K, Maeda H, Yanagisawa T, Takeuchi O, Kuronuma S, Sangai T, Shibahara Y, Murakumo Y, Saegusa M, Kanomata N, Nagasawa S, Yamaguchi R, Yoshida M, Kozuka Y, Matsumoto H, Tsugawa K, Maeda I; Accuracy of Breast Fine-Needle Aspiration Cytology of the Japanese Society of Clinical Cytology. Hoshino A, et al. Among authors: ohi y. Acta Cytol. 2024 Mar 29. doi: 10.1159/000538071. Online ahead of print. Acta Cytol. 2024. PMID: 38555634
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes.
Nishimura R, Fujiki Y, Taira T, Miyaki T, Kanemitsu S, Yotsumoto D, Teraoka M, Kawano J, Gondo N, Mitsueda R, Baba S, Ohi Y, Rai Y, Sagara Y, Sagara Y. Nishimura R, et al. Among authors: ohi y. Clin Breast Cancer. 2024 Feb 22:S1526-8209(24)00051-X. doi: 10.1016/j.clbc.2024.02.013. Online ahead of print. Clin Breast Cancer. 2024. PMID: 38472058
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, Kojima Y, Tsugawa K, Ohi Y, Sagara Y, Sato M, Ebata A, Harada-Shoji N, Suzuki T, Nakanishi M, Ohta T, Ishida T. Nakagawa S, et al. Among authors: ohi y. Breast Cancer Res Treat. 2024 Apr;204(3):453-463. doi: 10.1007/s10549-023-07209-2. Epub 2024 Jan 5. Breast Cancer Res Treat. 2024. PMID: 38180699 Free PMC article.
Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
Fujiki Y, Kashiwaba M, Sato M, Kawano J, Teraoka M, Kanemitsu S, Rai Y, Taira T, Sagara Y, Ohi Y, Jo U, Lee YW, Lee SB, Gong G, Shin YK, Kwon MJ, Sagara Y. Fujiki Y, et al. Among authors: ohi y. Breast Cancer. 2024 Jan;31(1):31-41. doi: 10.1007/s12282-023-01509-7. Epub 2023 Oct 9. Breast Cancer. 2024. PMID: 37812303 Free PMC article.
A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study.
Osako T, Matsuura M, Yotsumoto D, Takayama S, Kaneko K, Takahashi M, Shimazu K, Yoshidome K, Kuraoka K, Itakura M, Tani M, Ishikawa T, Ohi Y, Kinoshita T, Sato N, Tsujimoto M, Nakamura S, Tsuda H, Noguchi S, Akiyama F. Osako T, et al. Among authors: ohi y. Cancer. 2022 May 15;128(10):1913-1920. doi: 10.1002/cncr.34144. Epub 2022 Feb 28. Cancer. 2022. PMID: 35226357 Free PMC article. Clinical Trial.
219 results